Skip to main content

Market Overview

Benzinga's Top Analyst Calls From April 2, 2018


These headlines first appeared on Benzinga Pro.

  • Stifel on Walmart Inc (NYSE: WMT), Humana Inc (NYSE: HUM) WSJ report: Expansion of an existing prescription drug plan partnership 'is most likely,' would allow Walmart to learn more about healthcare industry. The firm's Mark Astrachan maintains a Hold rating and $99 price target on Walmart shares.
  • KeyBanc On Shopify (NYSE: SHOP): Sees recent ~19% pullback in stock as 'buy opportunity for a high-quality franchise,' says, 'despite concerns connected to Facebook, Shopify continues to drive the majority of GMV and merchants growth organically.'
  • Buckingham Research reiterates Buy rating on PVH Corp (NYSE: PVH) and raises price target from $176 to $187, says positive outlook is driven by “Global growth, accretive margin drivers, fx shift (from headwind to tailwind) and FCF-driven catalysts that support an upward earnings bias”
  • Morgan Stanley highlights takeaways from Dick's Sporting Goods Inc (NYSE: DKS) 10-K on Under Armour Inc. (NYSE: UAA): Under Armour sales no longer material for Dick's, further declines could represent 90 basis point drag for Dick's In 2018.
  • Alnylam Pharmaceuticals (NASDAQ: ALNY) shares down 23% since Mar. 28 following Pfizer update on ATTR-ACT; B. Riley FBR earlier issued note suggesting '8.3% decline in ALNY shares on 3/29 provide a buying opportunity'; Reiterates Buy rating, $200 price target
  • BMO initiates coverage on BioXcel Therapeutics Inc (NASDAQ: BTAI) with an Outperform rating and $23 price target. Firm believes BXCL501’s formulation and safety profile will enable BioXcel to consolidate a highly fragmented market in schizophrenia/bipolar and Alzheimer's dementia patients
  • Stifel on Post Holdings Inc (NYSE: POST) following mgmt. meetings: 'Our Buy rating remains confidently in place – we see strong upside for the shares from this level'
  • Argus upgrades Cardinal Health Inc. (NYSE: CAH) to buy; 'We expect sustainable EPS growth based on the company’s ability to improve margins in both its Pharmaceutical Distribution and Medical segments.'

Related Links

Benzinga's Top Upgrades, Downgrades For April 2, 2018

5 Biggest Price Target Changes For Monday


Related Articles (ALNY + BTAI)

View Comments and Join the Discussion!

Posted-In: Analyst Color Price Target Analyst Ratings

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at